Insurers are taking an even more cautious stance on Questcor's (QCOR -4.1%) Acthar, according to...
Insurers are taking an even more cautious stance on Questcor's (QCOR -4.1%) Acthar, according to a Citron Research report. The short seller is now claiming that Humana (HUM -1.5%) has issued a new Commercial Preauthorization document containing a new, specifically asterisked preauthorization for reimbursement for Acthar, which it contends is part of a pattern of insurers taking a more restrictive stance on authorization policy with regard to the drug's reimbursement.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Fri, 8:59AM)
at Nasdaq.com (Feb 12, 2015)
at Nasdaq.com (Feb 5, 2015)
at Investor's Business Daily (Feb 3, 2015)
at Nasdaq.com (Jan 9, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs